Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy

Background: Prostate cancer is usually considered as immune “cold” tumor with poor immunogenic response and low density of tumor-infiltrating immune cells, highlighting the need to explore clinically actionable strategies to sensitize prostate cancer to immunotherapy. In this study, we investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Zehua, Zhang, Weiwei, Dong, Baijun, Xin, Zhixiang, Ji, Yiyi, Su, Ruopeng, Shen, Kai, Pan, Jiahua, Wang, Qi, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274752/
https://www.ncbi.nlm.nih.gov/pubmed/35836810
http://dx.doi.org/10.7150/thno.73152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274752/
https://www.ncbi.nlm.nih.gov/pubmed/35836810
http://dx.doi.org/10.7150/thno.73152

Ejemplares similares